When selecting the appropriate formulation of Livmarli, the patient's weight and ability to swallow tablets should be considered. Livmarli tablets are supplied in 10mg, 15mg, 20mg, and 30mg dosage ...
Mirum Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in ...
Health Canada Authorizes Mirum's LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial ...
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of LIVMARLI ® ...
SAN CARLOS, Calif.--(BUSINESS WIRE)-- BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved a new ...
BASEL, Switzerland--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use ...
February 16, 2010 — The US Food and Drug Administration (FDA) has approved a new tablet formulation for the protease inhibitor ritonavir (Norvir, Abbott Laboratories, Inc) in combination with other ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved dolutegravir tablets and dolutegravir tablets for oral suspension to treat HIV infection, ...
Notes: Safety population, includes all randomized subjects who received at least one dose of study drug or placebo. Based on the encouraging weight loss, as well as the safety and tolerability results ...
Sporadic, unsubstantiated side effects were reported in the mass media after a formulation change of levothyroxine tablets induced patients to monitor thyroid-stimulating hormone levels and to ...
BASEL, Switzerland--(BUSINESS WIRE)-- BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results